Preclinical work shows the ALK inhibitor alectinib can enhance CAR T‑cell cytotoxicity against ALK‑driven neuroblastoma, researchers report. The study details combination experiments where targeted ALK suppression appeared to sensitize tumor cells and improve CAR T‑mediated killing, suggesting a potential path for combining small‑molecule ALK inhibitors with cell therapies in pediatric oncology. Authors argue the approach could overcome intrinsic resistance mechanisms in ALK‑mutant neuroblastoma; further validation in translational models and toxicology will be required before clinical testing. The results highlight a trend of combining targeted kinase inhibitors with adoptive cell therapies to deepen responses in solid tumors.